Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on February 6, 2008
J Am Soc Nephrol 19: 486-494, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007040419

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2007040419v1
19/3/486    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Weidemann, A.
Right arrow Articles by Willam, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weidemann, A.
Right arrow Articles by Willam, C.

BASIC RESEARCH

HIF Activation Protects From Acute Kidney Injury

Alexander Weidemann*,{dagger}, Wanja M. Bernhardt*, Bernd Klanke*, Christoph Daniel*, Björn Buchholz*, Valentina Câmpean{ddagger}, Kerstin Amann{ddagger}, Christina Warnecke*, Michael S. Wiesener{dagger}, Kai-Uwe Eckardt* and Carsten Willam*

* Department of Nephrology and Hypertension, {dagger} Interdisciplinary Centre for Clinical Research, and {ddagger} Department of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

Correspondence: Dr. Carsten Willam, Medical Clinic 4, Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen Nuremberg, Krankenhausstrasse 12, D - 91054 Erlangen, Germany. Phone: +49 9131-8539002; Fax: +49 9131-8539209; E-mail: carsten.willam{at}uk-erlangen.de

Received for publication April 6, 2007. Accepted for publication September 13, 2007.

The contribution of hypoxia to cisplatin-induced renal tubular injury is controversial. Because the hypoxia-inducible factor (HIF) pathway is a master regulator of adaptation to hypoxia, we measured the effects of cisplatin on HIF accumulation in vitro and in vivo, and tested whether hypoxic preconditioning is protective against cisplatin-induced injury. We found that cisplatin did not stabilize HIF-1{alpha} protein in vitro or in vivo under normoxic conditions. However, hypoxic preconditioning of cisplatin-treated proximal tubular cells in culture reduced apoptosis in an HIF-1{alpha}-dependent fashion and increased cell proliferation as measured by BrdU incorporation. In vivo, rats preconditioned with carbon monoxide before cisplatin administration had significantly better renal function than rats kept in normoxic conditions throughout. Moreover, the histomorphological extent of renal damage and tubular apoptosis was reduced by the preconditional treatment. Therefore, development of pharmacologic agents to induce renal HIF might provide a new approach to ameliorate cisplatin-induced nephrotoxicity.







HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP